Announcing a new publication for Acta Materia Medica journal. Ribonucleic acid for injection II is a clinical adjuvant cancer therapy treatment based on immunotherapy, which exerts its effects by enhancing immune function and suppressing tumor growth. However, the mechanism underlying the ameliorative effect on immunosuppressed hematopoietic dysfunction remains unclear.
This study confirms the immune-boosting and hematopoietic-promoting effects of ribonucleic acid for injection II, which has a wide distribution of molecular weights and is rich in amino acids and nucleotides. Ribonucleic acid for injection II influences the gut microbiota and serum metabolites to enhance immunity in immunosuppressed mice induced by CTX, while also mitigating bone marrow injury and increasing hematopoietic cells through mediating macrophage M1 differentiation, thereby improving hematopoietic dysfunction in mice.
# # # # # #
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submission Process
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at
Queries about the journal can be sent to editorialoffice@amm-journal.org.
Please visit to learn more about the journal.
Editorial Board: index.php/editorial-board/
There are no author submission or article processing fees.
Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal; Facebook (https://www.facebook.com/AMMjournal)
eISSN 2737-7946
# # # # # #
Yuan Li, Meng Teng and Siyu Li et al. Macrophage differentiation in enhancing hematopoietic function of ribonucleic acid for injection II via multi-omics analysis. Acta Materia Medica. 2024. Vol. 3(3):289-304. DOI: 10.15212/AMM-2024-0001
Journal
Acta Materia Medica
